Cost Sharing Program In Part D From Coalition Of Cancer Drug Manufacturers Rebuffed By OIG

 
• By Cathy Kelly

Federal watchdog group acknowledges proposed assistance program aligns with comments in a 2005 OIG advisory bulletin on patient assistance programs in Medicare Part D, but maintains the bulletin should not serve as a roadmap for a compliant program in this case.

Program Would Cover 90% Of Oncology Drug Use In Part D • Source: Shutterstock

More from Compliance

More from Pink Sheet